00:42:31 · Helmy Eltoukhy, Mark Jacobstein, Ross
So it's just a matter of time before we collect enough data to make some of those insights. But that's not to say that there won't be like a lot of advances made. It's just probably not 100% advances, but there'll be some advances in certain areas. [00:42:50] S1: Fantastic. We have time for, we got time for one more? We're sort of at five. Let's do one more. Who's got the last question here? All right. I'll take [00:43:00] S4: it. Go, Ross. So I heard what the next steps are for Guardant in terms of leveraging new technologies, but if you were exiting your PhD now and you had access to looking at what the new technologies are, what the new mountains are, and finding that valley between them, You know, with a blue sky, what would be the next direction for diagnostics? [00:43:21] S0: Yeah, I don't know. It's kind of hard. I think so much about what we're doing at Guardant. I don't know all the stuff that's being done in academia, but I would say that, I think I said this before, is that almost every great advancement in medicine has come from seeing something that was once invisible. So it's basically like going and let's take, you know, there are new tools. There are new sort of spatial biology tools. There are new like analysis tools that are 10x ing, 100x ing what was possible a year ago. So it would probably be at the intersection of one of those tools, sort of AI, obviously, and taking that and applying it in sort of a cool way to a new application. [00:44:08] S1: Fantastic. Helmy, thank you so much. Please join me in applause for Helmy.